You are on page 1of 5

4,706.

21

464.74
5,169.55

e) Other expenditure

196.24
589.28

Foreign Exchange Fluctuation ( Profit ) / Loss

Profit after finance costs but before Exeptional Items (56)

Exceptional Items

Profit / (Loss) from ordinary activities before tax

Extra ordinary / Prior Period Items

Net Profit / (Loss) for the period (10 - 11)

Minority Interest

Net Profit / (Loss) after taxes, monority interest and


share of profit / (Loss) of associates (12-13-14)

Paid-up equity share capital (Face Value Rs.10/-)

11

12

13

14

15

18

17

Reserves excluding Revaluation Reserve as per balance


sheet of previous accounting year
Earnings per share (Before Exceptional & Prior period
items) - Basic & Diluted
Earnings per share (After Exceptional & Prior period
items) - Basic & Diluted

Net Profit / (Loss) from ordinary activities after tax (8-9)

16

Tax Expense

10

(111.25)

(0.57)

3.46

11,906.34

1,945.51

1.60

1.76

12,017.59

1,945.51

311.95

311.95

(111.25)
-

(84.10)

227.85

(137.72)

132.30

(84.61)

360.14

(248.97)

114.69

922.86
(333.58)

474.84

48.04

283.04

805.92

319.60

805.92

1,105.13

312.22

1,105.13

5A

Profit/ (Loss) from operations before other income,


Finance Cost and Exceptional Items (1-2)
Profit / (Loss) from ordinary activities before finance cost
and exceptional items (3+4)
Finance Costs

Total Expenses

343.24

314.72

d) Depreciation and amortisation expenses

273.07

306.10

c) Employee benefits expenses

(467.94)

177.59

4245.62

5,512.13

6,274.69

3906.41

69.89

106.65

5442.24

(Unaudited)

(Unaudited)

6168.03

30/06/2015

Quarter Ended

3.17

3.28

10,442.53

1,852.91

587.31

587.31

19.64

606.95

160.66

767.61

767.61

77.01

300.82

1,145.45

1,145.45

4,714.46

248.16

385.45

252.56

(571.29)

4,399.58

1.03

5.22

10,643.23

1,852.91

200.70

200.70

(221.83)

(21.12)

47.69

26.57

1037.55

1,064.12

244.28

602.65

1,911.05

1,911.05

9,875.76

807.98

626.93

579.17

(290.35)

8152.03

11,786.82

176.55

5,859.90

11610.27

-48.77

(Unaudited)

Year Ended

1,199.81
1,510.00

759.17
508.38

30/09/2015

4.47

4.59

10,442.53

1,852.91

828.75

828.75

21.11

7.91

13.55

11,705.64

1,945.51

1,478.43

1,478.43

(639.62)

838.81

410.98
849.86

231.66

922.86

(0.51)

3.51

11,764.79

1,945.51

(99.59)

(3.31)

(102.90)

(137.72)

(240.62)

(84.15)

(324.77)

1,693.83
1,249.79

1,081.52

196.24
598.09

115.31

77.01

340.34

1,134.67

1,134.67

6,105.11

755.46

336.43

363.30

(805.82)

5,455.75

7,239.79

116.50

7,123.29

(Unaudited)

2,943.62

1,210.09

537.15

1,081.52

4,269.02

4,269.02

1,695.68

1,695.68

21,076.80

1,143.93

494.42

9,151.55

241.20

16981.87

25,345.82

225.13

25120.68

(Audited)

31/03/2015

(363.80)

7,753.37

10,847.23

47.01

10,800.22

(Unaudited)

30/09/2014

Half Year Ended


30/09/2015

5,908.67

(Unaudited)

30/09/2014

1.38

1.54

11,856.74

1,945.51

268.61

0.32

268.93

(84.10)

184.83

132.70

317.53

114.69

432.22

48.04

296.49

776.75

776.75

4,983.02

400.76

329.44

324.43

(970.75)

4,899.14

5,759.77

37.18

5,722.58

(Unaudited)

30/06/2015

Quarter Ended

3.31

3.42

10,289.86

1,852.91

613.46

0.24

613.71

19.64

633.35

161.90

795.25

795.25

335.29

1,130.54

1,130.54

5,436.51

415.46

391.74

309.73

(658.71)

4,978.29

6,567.05

-68.19

6,635.24

(Unaudited)

30/09/2014

0.87

5.05

11,764.79

1,945.51

613.46

(2.99)

166.03

(221.83)

(55.80)

48.55

(7.25)

1,037.55

1,030.31

196.24

636.83

1,863.38

1,863.38

11,136.18

1,204.26

665.87

687.72

(1776.57)

10,354.89

12,999.55

153.68

12,845.87

(Unaudited)

30/09/2015

4.40

4.28

10,289.86

1,852.91

793.87

0.41

794.28

21.11

815.39

233.06

1,048.45

1,048.45

601.06

1,649.51

1,649.51

10,106.47

742.34

771.47

592.19

(616.61)

8,617.08

11,755.98

27.88

11,728.10

(Unaudited)

30/09/2014

Half Year Ended

CONSOLIDATED
Rs. In Lacs ( Except for per share data )

STANDALONE
Rs. In Lacs ( Except for per share data )

Unaudited Financial Results for the quarter ended 30th Sept, 2015

b) Changes in inventories of finished goods and work in


progress

a) Cost of materials consumed Including Utilities

Expenses

Total Income from Operations (net)

b) Other Operating Income

a) Net Sales / Income from operations ( Net of Excise


Duty)

Income from Operations

Regd. Office : 7th Floor, Elite Square, 274, Perin Nariman Street,Fort,Mumbai- 400001.
Website: www.astecls.com, Tel no.022-61205600, Fax- 022-22618289, Email id: info@astecls.com

30/09/2015

Sr. No

PART I

ASTEC LifeSciences LTD


CIN No : L99999MH1994PLC076236

Year Ended

7.91

6.73

11,588.13

1,945.51

1,477.54

0.72

1,478.26

(639.62)

838.64

419.35

1,257.99

1,693.83

2,951.82

115.31

1,284.00

4,351.12

4,351.12

22,430.46

1,661.99

1,268.73

1,244.00

72.40

18,183.33

26,781.58

129.47

26,652.11

(Audited)

31/03/2015

5
2

Disposed of during the quarter

Remaining unresolved at the end of the quarter

25.29%

45.97%

45.74%

83.15%

Received during the quarter

30.00%
4,920,399

9.32%

54.26%

8,943,925

5,836,581

16.85%

8,698,075
44.71%

1,813,055

8,698,075
44.71%

Pending at the beginning of the quarter

INVESTOR COMPLAINTS

- Percentage of shares (as a % of the total share


capital of the company)
b) Non-encumbered
- No of shares
- Percentage of shares (as a % of the total
shareholding of promoters and promoter group
- Percentage of shares (as a % of the total share
capital of the company)
PARTICULARS

- No of shares
- Percentage of shareholding
Promoters and promoter group shareholding
a) Pledged / Encumbered
- No of shares
- Percentage of shares (as a % of the total
shareholding of promoters and promoter group

Public shareholding

PARTICULARS OF SHAREHOLDING

49.00%

84.00%

9,061,980

9.15%

15.76%

1,695,000

7,772,150
41.95%

45.97%

83.15%

8,943,925

9.32%

16.85%

1,813,055

8,698,075
44.71%

49.00%

84.00%

9,061,980

9.15%

15.76%

1,695,000

7,772,150
41.95%

36.38%

65.97%

7,096,828

18.81%

34.03%

3,660,152

8,698,075
44.71%

(Un Audited)
5,442.24
69.89
474.84
227.85
1.76
1.60

(Un Audited)
6,168.03
106.65
589.28
(248.97)
3.46
(0.57)

Other Operating Income

Profit / (Loss) from ordinary activities before tax


Net Profit Profit / (Loss) from ordinary activities after
tax
Earnings per share (Before Extra-ordinary & Prior period
items) - Basic & Diluted
Earnings per share (After Extra-ordinary & Prior period
items) - Basic & Diluted

Sd/(Ashok V Hiremath)
Managing Director
Friday, 06 th November, 2015

For Astec LifeSciences Limited

Net Sales / Income from operations ( Net of Excise Duty)

30/06/2015

Quarter Ended
30/09/2015

Particulars

Key standalone financial information of the company is given below :-

3.17

3.28

606.95

767.61

(48.77)

5,908.67

(Audited)

31/03/2015

30/09/2014

1.03

5.22

(21.12)

1,064.12

176.55

11,610.27

4.47

4.59

849.86

1,081.52

47.01

10,800.22

(Un Audited) (Un Audited)

30/09/2015

Half Year Ended

7.91

13.55

838.81

2,943.62

225.13

25,120.68

(Audited)

31/03/2015

Year ended

3 Above Financials include financial results of Behram Chemicals Pvt. Ltd. (65.63% subsidiary), Astec CropCare Pvt Ltd (100% Subsidiary of Astec) and
Astec Europe Sprl (50.10% subsidiary). The Financial Results of Comercializadora Agricola Agroastrachem Cia Ltda at Columbia (100% Subsidiary of
Astec) are not included as the company has not commercialised its operation.
4 Financials of Astec Europe Sprl for the period ended 30th September 2015 has not been consolidated in the financial statements, as the required
information was not avaialable. Further, we confirm that there is no material impact on the financials. However, audited financials till 31st
December 2014 has been consolidated for the said entity.
5 The company has only one reportable segment i.e. Agrochemicals.
6 Figures of the previous year have been regrouped/rearranged, wherever necessary.
7 Promoters of Astec and Godrej Agrovet Ltd (GAVL) have entered into Share Purchase Agreement dated 28th August 15 for transfer of 45.29% equity
shares to GAVL.
8 Exceptional items of Rs.92,286,284 consists Provision for non receivable Government Dues of Rs.28,068,164, Capital Work in Progress written-off of
Rs.33,316,153 and Provision for Doubtful Debts of Rs.30,901,967.
Prior Period items consists income of MAT Credit Receivable of Rs.6,955,779, Export incentive of Rs.8,154,248 and payment of statutory liabilities of
9
Rs.1,337,828

2 The above financial results have been subject to limited review by Statutory Auditor.

Notes:
The above unaudited financials results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their
1
meeting held on 06.11.2015.

10

PART II

30.00%
4,920,399
45.74%
25.29%

8,943,925
83.15%
45.97%

54.26%

5,836,581

8,698,075
44.71%

9.32%

16.85%

1,813,055

8,698,075
44.71%

49.00%

84.00%

9,061,980

9.15%

15.76%

1,695,000

7,772,150
41.95%

45.97%

83.15%

8,943,925

9.32%

16.85%

1,813,055

8,698,075
44.71%

49.00%

84.00%

9,061,980

9.15%

15.76%

1,695,000

7,772,150
41.95%

36.38%

65.97%

7,096,828

18.81%

34.03%

3,660,152

8,698,075
44.71%

Astec LifeSciences Limited


Statement of Liabilities and Assets as of 30th September 2015
Standalone
As at
9/30/2015

As at
3/31/2015

Consolidated
As at
As at
9/30/2015
3/31/2015

Equity and liabilities

Shareholders' funds
Share Capital
Reserves and surplus

194,550,550
1,190,633,940

194,550,550
1,170,563,722

194,550,550
1,176,479,260

194,550,550
1,158,813,340

1,385,184,490

1,365,114,272

1,371,029,810

1,353,363,890

209,762

508,977

Minority Interest

Non-current liabilities
Long-term borrowings
Deferred tax liabilities (net)
Other long term liabilities
Long-term Provisions

268,542,312
56,973,177
281,402,304
7,131,979

126,240,043
55,945,207
291,018,513
7,407,997

274,274,806
53,124,332
289,605,714
7,131,979

132,204,986
52,096,362
297,681,922
7,407,997

614,049,772

480,611,760

624,136,831

489,391,267

742,965,547
772,369,627
130,104,805
23,465,647

725,720,571
830,116,530
120,788,416
45,213,769

790,987,033
905,990,503
145,345,312
41,280,139

773,845,698
838,335,068
128,398,125
47,174,764

1,668,905,626
3,668,139,889

1,721,839,286
3,567,565,318

1,883,602,986
3,878,979,390

1,787,753,654
3,631,017,788

1,220,371,802
314,217
172,983,447
9,981,395
267,220,119

1,271,954,951
382,583
122,470,471
9,981,395
192,288,344

1,226,328,847
48,753,425
172,983,447
237,800
268,232,145

1,330,261,287
382,583
122,470,471
237,800
193,300,370

1,670,870,980

1,597,077,744

1,716,535,664

1,646,652,511

1,136,726
718,759,426
890,391,645
112,573,029
274,408,082

917,436
623,983,064
976,090,704
112,160,707
257,335,662

1,136,726
912,633,543
1,010,683,936
117,841,346
120,148,175

917,436
719,294,310
1,048,305,436
120,199,513
95,648,580

1,997,268,909
3,668,139,889

1,970,487,574
3,567,565,318

2,162,443,726
3,878,979,390

1,984,365,276
3,631,017,788

Current liabilities
Short-term borrowings
Trade payables
Other current liabilities
Short-term provisions

Total
Assets

Non-current assets
Fixed assets
Tangible Assets
Intangible Assets
Capital work-in-progress
Non-current investments
Long-term loans and advances

Current assets
Current investments
Inventories
Trade receivables
Cash and cash equivalents
Short-term loans and advances

Total
For Astec LifeSciences Limited

Sd/(Ashok V Hiremath)
Managing Director
Friday, 06 th November, 2015

You might also like